The Cardioform ASD Occluder (Gore Medical) has received US Food and Drug Administration (FDA) premarket approval (PMA) for use in the percutaneous closure of ostium secundum atrial septal defects (ASDs). A press release from the company says that the FDA approval was supported by data collected from the pivotal stage of the Gore ASSURED clinical study which demonstrated 100% closure success at six-months in patients with a successful implant.
The press release also outlines the properties of the Cardioform ASD Occluder, which has an anatomically adaptable waist that conforms to the defect to close ASDs from 8–35 mm in diameter, including those without a retro-aortic rim, by facilitating optimal tissue ingrowth while maintaining thromboresistance. Gore Medical says that as the company’s latest extension to the Gore Cardioform Occluder family it builds on a legacy of safety outcomes.
The Gore ASSURED clinical study, says the company, met its safety, closure, and technical success primary endpoints. It evaluated the safety and efficacy of ASD closure using the Gore Cardioform ASD Occluder in 125 patients with evidence of right heart volume overload demonstrating the need for defect closure. Patients were aged between two and 84 years in 22 investigation sites, including 15 children’s hospitals.
In the press release, Matthew J Gillespie (Children’s Hospital of Philadelphia, Pennsylvania, USA), co-principal investigator of the ASSURED study, says: “The FDA approval of the Gore Cardioform ASD Occluder is a significant milestone for innovation in the minimally invasive treatment of ASDs. This soft, conformable device was not previously available for this range of defects but is now an option for larger defects that typically have a greater risk for complications, including right heart enlargement, atrial fibrillation, and pulmonary hypertension. The ability to retrieve and reposition the Gore Cardioform ASD Occluder helps me ensure proper positioning and offers me confident closure.”
Source CardiovascularNews
Duc Tin Clinic
Tin tức liên quan
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389